TOP TEN perturbations for 1459_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1459_at
Selected probe(set): 205171_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1459_at (205171_at) across 6537 perturbations tested by GENEVESTIGATOR:

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):3.2194786
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):2.9373941
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):2.7667818
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):-2.5756063
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

pediatric meningococcal sepsis study 2 (early) / normal blood sample

Relative Expression (log2-ratio):-2.5017776
Number of Samples:2 / 3
Experimental pediatric meningococcal sepsis study 2 (early)
Whole blood drawn from children with meningococcal sepsis at time of admission to the pediatric intensive care unit (0h).
Control normal blood sample
Whole blood drawn from matched control subjects.

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-2.4881134
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample

Relative Expression (log2-ratio):-2.4866247
Number of Samples:2 / 2
Experimental T-cell activation study 3
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs.
Control resting CD4 T-lymphocyte (crude fraction) sample
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction.

pediatric meningococcal sepsis study 2 (late) / normal blood sample

Relative Expression (log2-ratio):-2.1896849
Number of Samples:5 / 3
Experimental pediatric meningococcal sepsis study 2 (late)
Whole blood drawn from children with meningococcal sepsis 24 or 72 hours after admission to the pediatric intensive care unit.
Control normal blood sample
Whole blood drawn from matched control subjects.

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-2.156479
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

G-CSF study 1 / untreated leukocyte sample

Relative Expression (log2-ratio):-2.1513262
Number of Samples:5 / 5
Experimental G-CSF study 1
Peripheral blood samples from normal donors for allogenic PBSC transplantation obtained after administration of granulocyte-colony stimulating factor (G-CSF; 10μg/kg/day for five days). Whole blood leukocyte RNA was purified from each sample and used to generate cRNAs.
Control untreated leukocyte sample
Peripheral blood samples from normal donors for allogenic PBSC transplantation obtained before administration of granulocyte-colony stimulating factor (G-CSF). Whole blood leukocyte RNA was purified from each sample and used to generate cRNAs.